CY1115731T1 - Παραγοντας αναστολης toy mic-1 - Google Patents

Παραγοντας αναστολης toy mic-1

Info

Publication number
CY1115731T1
CY1115731T1 CY20141100862T CY141100862T CY1115731T1 CY 1115731 T1 CY1115731 T1 CY 1115731T1 CY 20141100862 T CY20141100862 T CY 20141100862T CY 141100862 T CY141100862 T CY 141100862T CY 1115731 T1 CY1115731 T1 CY 1115731T1
Authority
CY
Cyprus
Prior art keywords
mic
toy
subject
present
suspension factor
Prior art date
Application number
CY20141100862T
Other languages
English (en)
Inventor
Samuel Norbet Briet
Asne Rhoda Bauskin
Original Assignee
St Vincent's Hospital Sydney Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35149777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115731(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2004901957A external-priority patent/AU2004901957A0/en
Application filed by St Vincent's Hospital Sydney Limited filed Critical St Vincent's Hospital Sydney Limited
Publication of CY1115731T1 publication Critical patent/CY1115731T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/02—Nutritional disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/303—Eating disorders, e.g. anorexia, bulimia

Abstract

Η παρούσα εφεύρεση σχετίζεται με μια μέθοδο ελέγχου της όρεξης και/ή του σωματικού βάρους σε ένα υποκείμενο, με την εν λόγω μέθοδο να περιλαμβάνει χορήγηση στο εν λόγω υποκείμενο μιας αποτελεσματικής ποσότητας παράγοντα ρύθμισης του MIC-1, όπου ο εν λόγω παράγοντας αυξάνει ή μειώνει την ποσότητα του MIC-1 που υπάρχει στο εν λόγω υποκείμενο, ή αναστέλλει ή ενισχύει την βιολογική ενεργότητα του MIC-1 που υπάρχει στο εν λόγω δείγμα.
CY20141100862T 2004-04-13 2014-10-22 Παραγοντας αναστολης toy mic-1 CY1115731T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004901957A AU2004901957A0 (en) 2004-04-13 Method for modulating appetite
EP11183884.3A EP2441466B1 (en) 2004-04-13 2005-04-13 MIC-1 inhibiting agent

Publications (1)

Publication Number Publication Date
CY1115731T1 true CY1115731T1 (el) 2017-01-25

Family

ID=35149777

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100862T CY1115731T1 (el) 2004-04-13 2014-10-22 Παραγοντας αναστολης toy mic-1

Country Status (12)

Country Link
US (6) US8192735B2 (el)
EP (4) EP1734986B1 (el)
JP (4) JP5448338B2 (el)
CA (2) CA2905125C (el)
CY (1) CY1115731T1 (el)
DK (2) DK2929891T3 (el)
ES (3) ES2788868T3 (el)
HK (2) HK1168274A1 (el)
PL (2) PL2929891T3 (el)
PT (2) PT2441466E (el)
SI (1) SI2441466T1 (el)
WO (1) WO2005099746A1 (el)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5448338B2 (ja) * 2004-04-13 2014-03-19 セントビンセンツ ホスピタル シドニー リミテッド 食欲を調節する方法
JP5309026B2 (ja) * 2006-08-04 2013-10-09 メディツィニッシュ ホホシュール ハノーバー Ｇｄｆ−１５に基づく心臓インターベンションの危険性を評価するための手段および方法
US20100278843A1 (en) * 2007-08-16 2010-11-04 St. Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
CN101896192A (zh) * 2007-10-09 2010-11-24 圣文森特医院悉尼有限公司 一种通过去除或灭活巨噬细胞抑制因子-1而治疗恶病质的方法
ES2434996T3 (es) * 2008-10-31 2013-12-18 St Vincent's Hospital Sydney Limited Métodos de pronóstico en enfermedad renal crónica
WO2012138919A2 (en) 2011-04-08 2012-10-11 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3683228A3 (en) 2012-01-26 2020-07-29 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
US9550819B2 (en) 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US20150239968A1 (en) 2012-09-26 2015-08-27 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
DK2934584T3 (da) * 2012-12-21 2020-05-18 Aveo Pharmaceuticals Inc Anti-gdf15-antistoffer
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
CA2899170C (en) 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
LT3027642T (lt) 2013-07-31 2020-10-12 Amgen Inc. Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai
GB2524552B (en) * 2014-03-26 2017-07-12 Julius-Maximilians-Universitãt Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
GB2524553C (en) * 2014-03-26 2017-07-19 Julius-Maximilians-Universitãt Würzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
HUE047398T2 (hu) * 2014-03-26 2020-04-28 Univ Wuerzburg J Maximilians Növekedési és differenciálódási faktor 15 (GDF-15) elleni monoklonális antitestek és azok alkalmazásai rákos sorvadás és rák kezelésére
US20170137505A1 (en) * 2014-06-20 2017-05-18 Aveo Pharmaceuticals, Inc. Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
BR112016029820A2 (pt) * 2014-06-20 2017-10-24 Aveo Pharmaceuticals Inc tratamento de doença renal crônica e outras disfunções renais usando um modulador de gdf15
EP3157942B1 (en) * 2014-06-23 2020-06-17 Novartis AG Site specific protein modifications
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3160496B1 (en) 2014-06-24 2021-03-03 Novo Nordisk As MIC-1 FUSION PROTEINS AND RELATED USES
WO2016018931A1 (en) 2014-07-30 2016-02-04 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US20170306008A1 (en) * 2014-09-25 2017-10-26 Aveo Pharmaceuticals, Inc. Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
AU2015339130C1 (en) 2014-10-31 2021-03-18 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CN107108754A (zh) * 2014-12-22 2017-08-29 诺和诺德股份有限公司 α‑1‑抗胰蛋白酶(A1AT)融合蛋白及其用途
EP4321866A3 (en) 2015-10-02 2024-03-20 Julius-Maximilians-Universität Würzburg Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
KR20180054868A (ko) 2015-10-02 2018-05-24 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 인간 증식 및 분화 인자 15 (gdf-15)의 저해제와 면역 체크포인트 차단제를 이용한 병용 요법
US11105818B2 (en) 2016-01-15 2021-08-31 Novo Nordisk A/S MIC-1 receptor and uses thereof
CN108700573B (zh) * 2016-02-29 2021-06-11 公立大学法人横滨市立大学 检测去势抵抗性前列腺癌的方法和检测试剂
PE20190126A1 (es) 2016-03-31 2019-01-17 Ngm Biopharmaceuticals Inc Proteinas de union y metodos de uso de las mismas
CN109071647B (zh) 2016-04-27 2022-11-22 诺华股份有限公司 抗生长分化因子15的抗体及其用途
MA46523A (fr) * 2016-10-12 2019-08-21 Janssen Biotech Inc Procédés de criblage de modulateurs d'une activité biologique de type gdf15
JP7134960B2 (ja) * 2016-12-06 2022-09-12 セントビンセンツ ホスピタル シドニー リミテッド 肥満及び摂食障害の治療
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
WO2019004550A1 (ko) * 2017-06-26 2019-01-03 강원대학교 산학협력단 Mic-1 단백질에 특이적으로 결합하는 항체 및 이의 용도
JP7127422B2 (ja) * 2017-08-30 2022-08-30 東ソー株式会社 癌を検出する方法及び検出試薬
JP2020533302A (ja) 2017-09-10 2020-11-19 ノヴォ ノルディスク アー／エス 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１
PE20201350A1 (es) 2018-04-09 2020-11-30 Amgen Inc Proteinas de fusion del factor de diferenciacion de crecimiento 15
BR112021003173A2 (pt) 2018-08-20 2021-05-11 Pfizer Inc. anticorpos anti-gdf15, composições e métodos de uso
US11810670B2 (en) 2018-11-13 2023-11-07 CurieAI, Inc. Intelligent health monitoring
EP4065597A4 (en) 2019-11-26 2024-01-24 Yuhan Corp LONG-ACTING GDF15 FUSION PROTEINS AND PHARMACEUTICAL COMPOSITION THEREFROM
EP4314071A1 (en) 2021-03-31 2024-02-07 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
CA3219645A1 (en) 2021-05-21 2022-11-24 Yuhan Corporation Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist
KR20220157911A (ko) 2021-05-21 2022-11-29 주식회사유한양행 Gdf15 변이체를 포함하는 비알코올성 지방간질환 또는 비알코올성 지방간염의 예방 또는 치료용 조성물
IL310535A (en) 2021-08-10 2024-03-01 Byomass Inc Anti-GDF15 antibodies, compositions and uses thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1997000958A1 (en) 1995-06-22 1997-01-09 St. Vincent's Hospital Sydney Limited NOVEL TGF-β LIKE CYTOKINE
WO1999006445A1 (en) * 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
EP1117805A2 (en) 1998-10-07 2001-07-25 STRYKER CORPORATION (a Michigan corporation) Modified tgf-beta superfamily proteins
DE60142372D1 (de) 2000-04-20 2010-07-22 St Vincents Hosp Sydney Diagnostischer Assay mit makrophagenhemmendem Zytokin-1 (MIC-1)
US7141661B2 (en) * 2000-09-08 2006-11-28 The United States Of America As Represented By The Department Of Health And Human Services Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
US7157235B2 (en) * 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
JP5448338B2 (ja) 2004-04-13 2014-03-19 セントビンセンツ ホスピタル シドニー リミテッド 食欲を調節する方法
WO2006078161A1 (en) * 2005-01-24 2006-07-27 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
EP2396025A2 (en) 2009-02-12 2011-12-21 Stryker Corporation Peripheral administration of proteins including tgf-beta superfamily members for systemic treatment of disorders and disease

Also Published As

Publication number Publication date
JP2013209376A (ja) 2013-10-10
US20110123454A1 (en) 2011-05-26
DK2441466T3 (da) 2014-10-27
EP2929891A1 (en) 2015-10-14
JP5767667B2 (ja) 2015-08-19
SI2441466T1 (sl) 2015-01-30
EP2774620A1 (en) 2014-09-10
PT2441466E (pt) 2014-09-09
US20150183861A1 (en) 2015-07-02
PL2929891T3 (pl) 2020-08-24
JP2011190262A (ja) 2011-09-29
US20180346560A1 (en) 2018-12-06
US8946146B2 (en) 2015-02-03
EP1734986A4 (en) 2009-07-22
DK2929891T3 (da) 2020-05-11
JP5448338B2 (ja) 2014-03-19
CA2561877C (en) 2017-03-14
EP2929891B1 (en) 2020-03-11
EP2441466A1 (en) 2012-04-18
EP1734986A1 (en) 2006-12-27
CA2561877A1 (en) 2005-10-27
JP2014051511A (ja) 2014-03-20
CA2905125C (en) 2017-02-07
JP5806275B2 (ja) 2015-11-10
JP2007532586A (ja) 2007-11-15
HK1168274A1 (en) 2012-12-28
ES2518865T3 (es) 2014-11-05
ES2555956T3 (es) 2016-01-11
US20090004181A1 (en) 2009-01-01
US20160289320A1 (en) 2016-10-06
HK1215932A1 (zh) 2016-09-30
PL2441466T3 (pl) 2015-01-30
EP1734986B1 (en) 2015-11-11
US20210340243A1 (en) 2021-11-04
EP2441466B1 (en) 2014-07-23
US8192735B2 (en) 2012-06-05
ES2788868T3 (es) 2020-10-23
PT2929891T (pt) 2020-04-08
WO2005099746A1 (en) 2005-10-27
CA2905125A1 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
CY1115731T1 (el) Παραγοντας αναστολης toy mic-1
CY1121162T1 (el) M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου
CY1112383T1 (el) Αναστολεις της πρωτεϊνης ενεργοποιησης της 5-λιποξυγενασης (flap)
CY1119598T1 (el) Ανθεκτικες σε θραυση μορφες δοσολογησης με επιβραδυντικη απελευθερωση
CY1120434T1 (el) Πρωτεϊνες προσδεσης il-1
CY1120384T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
CY1118472T1 (el) Υποκατεστημενα ακυλανιλιδια και μεθοδοι χρησης αυτων
ME00380B (me) Amtagonisti aktivin-actriia i primjene za stimulaciju rasta kosti
CY1115860T1 (el) Χρηση hif αλφα σταθεροποιητων για ενισχυση της ερυθροποιησης
ATE527365T1 (de) Il-15r alpha -sushi domäne als selektiver und effizienter verstärker der il-15-wirkung durch il-15rbeta/gamma , in hyperagonist il-15 ralpha sushi -il 15 fusionsproteine .
CY1111714T1 (el) Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf).
DK1487856T3 (da) KDR-specifikke humane antistoffer og deres anvendelse
DE602005021694D1 (de) Kombinationstherapien gegen multiple toll-like-rezeptoren und ihre verwendung
CY1115437T1 (el) Υδροξυμεθυλοκυκλοεξυλαμινες
CY1111354T1 (el) Συστασεις αναστολεα ddp iv
ATE474578T1 (de) Verwendung von flibanserin bei der behandlung von prämenstruellen störungen
NL1026829A1 (nl) Gemodificeerde humane IGF-1R-antilichamen.
ECSP077222A (es) Anticuerpos monoclonales humanos contra interleucina-4 humana (il-4)
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
CY2014007I2 (el) Μεθοδοι για την αγωγη διαταραχων ή παθησεων που συσχετιζονται με υπερλιπιδαιμια και υπερχοληστερολαιμια ενω ελαχιστοποιουνται οι παρενεργειες
ATE395082T1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
DE602004019995D1 (de) Verwendung von n-arylhydrazinderivaten für die bekämpfung von schädlingen in und an tieren
TR201901390T4 (tr) Demodikoza karşı madde.
ATE497737T1 (de) Implantate beschichtet mit aptameren, die die adhäsion von endothelialen vorläuferzellen vermitteln
CY1113310T1 (el) Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων